179例甲状腺乳头状癌患者BRAFV600E基因突变回顾性分析

目的:检测BRAFV600E基因突变在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中的发生情况,分析BRAFV600E基因突变与临床参数、合并桥本氏甲状腺炎和结节性甲状腺肿的关系.方法:回顾性分析第四军医大学西京医院核医学科2015年6月1日至2016年5月31日所收治的甲状腺乳头状癌患者179例,由病理科检测BRAFV600E突变情况.结果:179例患者病理结果显示BRAFV600E基因突变率为61.5％.BRAFV600E基因突变率与年龄和淋巴结转移个数相关(P＜0.05),且随着年龄增大,突变的风险略有增高(OR=1.064).合并结节性甲状腺肿的甲状腺乳头状癌患者48例,突变率75％;未合并结节性甲状腺肿的甲状腺乳头状癌患者131例,突变率56.5％,差异有统计学意义(P=0.024),且合并结节性甲状腺肿是BRAFV600E基因突变的危险因素(OR=2.349).结论:甲状腺乳头状癌患者的BRAFV600E基因突变率与患者年龄、颈部淋巴结转移个数以及是否合并结节性甲状腺肿具有相关性.

Analysis of 179 BRAFV600E mutation in papillary thyroid carcinoma patients

Objective:To analyze the relations between BRAFV600E mutation and some pathological parameters in papillary thyroid carcinoma(PTC),and to investigate BRAFV600E mutation in PTC coexisting with Hashimoto's thyroidi tis or nodular goiter.Methods:To retrospectively analyze data of 179 cases of post-operation PTC patients.Clinical datas were reviewed and evaluated by SPSS 21.0 statistical software package.Results:Among the 179 PTC patients,the presence of BRAFV600E mutation was 61.5％.There is a correlation between BRAFV600E mutation rate and age or numbers of lymph node metastasis (P ＜ 0.05 respectively).And age is a risk factor of BRAFV600E mutation(OR =1.064).The BRAFV600E mutation rate was higher in PTC patients coexisting with nodular goiter than patients without nodular goiter (P =0.024).And nodular goiter is also a risk factor (OR =2.349).Conclusion:The BRAFV600E mutation rates have correlation with age,numbers of lymph node metastasis and whether coexisting with nodular goiter.